2021
Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence
Vrachatis DA, Papathanasiou KA, Kossyvakis C, Giotaki SG, Raisakis K, Iliodromitis KE, Reimers B, Stefanini GG, Cleman M, Sianos G, Lansky A, Deftereos SG, Giannopoulos G. Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence. Diabetes Research And Clinical Practice 2021, 174: 108724. PMID: 33647332, DOI: 10.1016/j.diabres.2021.108724.Peer-Reviewed Original ResearchConceptsDiabetes mellitusAtrial fibrillationType 1 diabetes mellitusIndependent risk factorAtrial fibrillation managementAtrial fibrillation riskAF developmentInsulin deficiencyGlycemic variabilityRisk factorsClinical dataClinical studiesMicrovascular sequelaeAtrial arrhythmogenesisAnimal studiesAtrial myocytesClinical practiceArrhythmia initiationStructural remodelingClinical implicationsT1DMOxidative stressPI3KGlucose transportationMellitus
2015
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials
Brener SJ, Mehran R, Lansky AJ, Ayele GM, Stone GW. Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. European Heart Journal Acute Cardiovascular Care 2015, 5: 449-454. PMID: 26722003, DOI: 10.1177/2048872615624848.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHORIZONS-AMI trialCoronary syndromeAspirin pretreatmentMyocardial infarctionCardiac deathStent thrombosisSegment elevation acute coronary syndromesST-segment elevation myocardial infarctionElevation acute coronary syndromeAcute coronary syndrome patientsLarge randomized clinical trialsAdverse ischemic eventsTarget vessel revascularizationCoronary syndrome patientsIndependent risk factorElevation myocardial infarctionLarge prospective studiesHigh-risk cohortIncidence of deathRandomized clinical trialsMultivariable regression analysisPrior revascularizationVessel revascularizationIschemic events
2013
Pre-hypertension: another 'pseudodisease’?
Meier P, Messerli FH, Baumbach A, Lansky AJ. Pre-hypertension: another 'pseudodisease’? BMC Medicine 2013, 11: 211. PMID: 24229371, PMCID: PMC3848832, DOI: 10.1186/1741-7015-11-211.Peer-Reviewed Original ResearchConceptsBlood pressureCardiovascular riskRisk factorsCommon cardiovascular risk factorsCardiovascular risk factorsEnd-organ damageIndependent risk factorRisk markersHealthy peopleHypertensionBMC MedicineMmHgPseudodiseaseExpert CommitteeSignificant proportionSignificant markersRiskMarkersSystolicPatientsDisease
2001
Effect of gender on the outcomes of contemporary percutaneous coronary intervention
Peterson E, Lansky A, Kramer J, Anstrom K, Lanzilotta M, Investigators F. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. The American Journal Of Cardiology 2001, 88: 359-364. PMID: 11545754, DOI: 10.1016/s0002-9149(01)01679-4.Peer-Reviewed Original ResearchConceptsIndependent risk factorRisk factorsBaseline clinical risk factorsHigher vascular complication ratesContemporary percutaneous coronary interventionPercutaneous coronary intervention (PCI) technologyRisk adjustmentExtensive coronary diseaseProcedural mortality rateVascular complication ratesClinical risk factorsPercutaneous coronary interventionBody surface areaPatient body sizeHospital revascularizationAssociation of genderComorbid illnessesVascular complicationsComplication rateCoronary interventionCoronary diseaseProcedural outcomesFemale genderIndependent riskPCI cases
2000
Optimally deployed stents in the treatment of restenotic versus de novo lesions
Gruberg L, Hong M, Mintz G, Mehran R, Waksman R, Dangas G, Kent K, Pichard A, Satler L, Lansky A, Kornowski R, Stone G, Leon M. Optimally deployed stents in the treatment of restenotic versus de novo lesions. The American Journal Of Cardiology 2000, 85: 333-337. PMID: 11078302, DOI: 10.1016/s0002-9149(99)00742-0.Peer-Reviewed Original ResearchConceptsDe novo lesionsOptimal stent deploymentTarget lesion revascularizationEvent-free survivalVein graft lesionsNovo lesionsLong-term outcomesMinimal lumen diameterRestenotic lesionsStent deploymentLesion revascularizationGraft lesionsDiabetes mellitusMyocardial infarctionHigh incidenceNon-Q-wave myocardial infarctionDe novo lesions groupFinal minimal lumen diameterLumen diameterSaphenous vein graft lesionsIndependent risk factorDe novo groupIncidence of deathStent deployment techniquesStatistical significant difference